These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1606063)

  • 1. Recognition of tumor-associated antigens by T lymphocytes: from basic concepts to new approaches.
    Cerottini JC; von Fliedner V; Boon T
    Ann Oncol; 1992 Jan; 3(1):11-6. PubMed ID: 1606063
    [No Abstract]   [Full Text] [Related]  

  • 2. [Induction and functional analysis of cytotoxic T lymphocytes specific for the novel tumor-associated antigen CML66].
    Suemori K
    Rinsho Ketsueki; 2009 Aug; 50(8):604-10. PubMed ID: 19915374
    [No Abstract]   [Full Text] [Related]  

  • 3. Genes coding for antigens recognized on human tumors by autologous cytolytic T lymphocytes.
    Coulie P; Weynants P; Muller C; Lehmann F; Herman J; Baurain JF; Boon T
    Ann N Y Acad Sci; 1993 Aug; 690():113-9. PubMed ID: 8368730
    [No Abstract]   [Full Text] [Related]  

  • 4. The journey from autologous typing to SEREX, NY-ESO-1, and cancer/testis antigens.
    Chen YT
    Cancer Immun; 2012; 12():8. PubMed ID: 22896753
    [No Abstract]   [Full Text] [Related]  

  • 5. [Tumor specific antigen and cytotoxic T lymphocytes].
    Uenaka A; Nakayama E
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():568-73. PubMed ID: 15861712
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor-specific T-cell immunity: ready for prime time?
    Greenberg PD; Riddell SR
    J Natl Cancer Inst; 1992 Jul; 84(14):1059-61. PubMed ID: 1619675
    [No Abstract]   [Full Text] [Related]  

  • 7. Human tumor antigens recognized by T lymphocytes.
    Boon T; van der Bruggen P
    J Exp Med; 1996 Mar; 183(3):725-9. PubMed ID: 8642276
    [No Abstract]   [Full Text] [Related]  

  • 8. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.
    Boon T; Coulie P; Marchand M; Weynants P; Wölfel T; Brichard V
    Important Adv Oncol; 1994; ():53-69. PubMed ID: 8206495
    [No Abstract]   [Full Text] [Related]  

  • 9. CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas.
    Pascual-García M; Bértolo C; Nieto JC; Serrat N; Espinosa Í; D'Angelo E; Muñoz R; Rovira R; Vidal S; Prat J
    Hum Pathol; 2016 Oct; 56():180-8. PubMed ID: 27346574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"].
    Peiper M; Goedegebuure PS; Eberlein TJ; Zornig C
    Zentralbl Chir; 1997; 122(3):141-8. PubMed ID: 9206906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining tumor antigens: mRNA, protein or cytotoxicity?
    Lim SH; Periman P; Klug P; Weidanz J; Whitton V; Chiriva-Internati M; Wang Z; Wright S
    Trends Immunol; 2002 May; 23(5):236-7; author reply 237-8. PubMed ID: 12102740
    [No Abstract]   [Full Text] [Related]  

  • 12. Teaching the immune system to fight cancer.
    Boon T
    Sci Am; 1993 Mar; 268(3):82-9. PubMed ID: 8316825
    [No Abstract]   [Full Text] [Related]  

  • 13. Human tumour antigens recognized by T cells: new perspectives for anti-cancer vaccines?
    Coulie PG
    Mol Med Today; 1997 Jun; 3(6):261-8. PubMed ID: 9211417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [RNA-loaded dendritic cells].
    Hinoda Y
    Nihon Rinsho; 2005 Apr; 63 Suppl 4():613-8. PubMed ID: 15861719
    [No Abstract]   [Full Text] [Related]  

  • 15. Genes coding for tumor-specific rejection antigens.
    Boon T; Van den Eynde B; Hirsch H; Moroni C; De Plaen E; van der Bruggen P; De Smet C; Lurquin C; Szikora JP; De Backer O
    Cold Spring Harb Symp Quant Biol; 1994; 59():617-22. PubMed ID: 7587121
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens.
    Romero P
    Springer Semin Immunopathol; 1996; 18(2):185-98. PubMed ID: 8908699
    [No Abstract]   [Full Text] [Related]  

  • 17. [Tumor antigen-specific cytotoxic T lymphocytes and cancer immunotherapy - review].
    Liu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Apr; 12(2):244-8. PubMed ID: 15157343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological ignorance of silent antigens as an explanation of tumor evasion.
    Chen L
    Immunol Today; 1998 Jan; 19(1):27-30. PubMed ID: 9465485
    [No Abstract]   [Full Text] [Related]  

  • 19. Identification of HLA-A*0201/-A*2402-restricted CTL epitope-peptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response.
    Kawamoto M; Tanaka F; Mimori K; Inoue H; Kamohara Y; Mori M
    Oncol Rep; 2011 Feb; 25(2):469-76. PubMed ID: 21165574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunology of metastasis. Can the immune response cope with disseminated tumor?
    Frost P; Kerbel RS
    Cancer Metastasis Rev; 1983; 2(3):239-56. PubMed ID: 6231096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.